Reuters logo
BRIEF-Orexigen Therapeutics sees Q4 total revenue $13.4-$13.9 mln
2017年2月17日 / 下午2点25分 / 8 个月前

BRIEF-Orexigen Therapeutics sees Q4 total revenue $13.4-$13.9 mln

Feb 17 (Reuters) - Orexigen Therapeutics Inc

* Orexigen Therapeutics Inc - Expects total revenue for q4 of 2016 to be between approximately $13.4 million to $13.9 million

* Expects U.S. net sales for contrave for Q4 of 2016 to be between approximately $11.5 million to $12.0 million

* Orexigen Therapeutics Inc - Company also expects U.S. net sales for contrave for q4 of 2016 to be between approximately $11.5 million to $12.0 million

* Q4 revenue view $12.5 million -- Thomson Reuters I/B/E/S

* Orexigen Therapeutics Inc - Expects total revenue for year ended December 31, 2016 to be between approximately $33.3 million to $33.8 million

* Orexigen Therapeutics - entered into separate privately negotiated exchange agreements with certain holders of 2.75% convertible senior notes due 2020

* Q4 revenue view $12.5 million -- Thomson Reuters I/B/E/S

* Fy2016 revenue view $34.0 million -- Thomson Reuters I/B/E/S

* Orexigen Therapeutics - new notes bear interest at fixed rate of 2.75% per year, payable semiannually in arrears on june 1 and december 1 of each year Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below